The Impact of Interscalene Block on Sleep Disordered Breathing

Women's College Hospital76 enrolled

Overview

This is a randomized controlled trial evaluating the impact of interscalene block on worsening of upper airway collapse in sleep disordered breathing for patients undergoing ambulatory shoulder surgery.

Sleep disordered Breathing (SDB), closely associated with obesity, is a highly prevalent, serious, and often unrecognized breathing disorder resulting from repeated upper airway collapse, decreased oxygen levels, and a very high risk of life threatening complications at the time of surgery. Current guidelines recommend using regional as opposed to general anesthesia in SDB patients to minimize risks and the use of strong narcotic medications. It is unclear whether interscalene block in use for analgesia (pain relief) may actually worsen the severity of SDB by invariably freezing the phrenic nerve, thereby temporarily paralyzing the diaphragm. This novel clinical trial will examine whether or not ISB increases the rate of upper airway obstruction or collapse during sleep and other dangerous postoperative complications seen in patients with SDB following shoulder surgeries. The Primary Objective of the study is to evaluate the impact of ISB on the oxygen desaturation index (sleep apnea severity) in untreated SDB patients undergoing ambulatory shoulder surgery compared to patients who do not receive ISB. Secondary Objectives are: 1) To evaluate the impact of hemidiaphragmatic paresis on impairment in pulmonary function; 2) To evaluate the impact of impairment in pulmonary function on the oxygen desaturation index (ODI); 3) To assess the incidence of important perioperative clinical outcomes such as hypoxemia, recurrent respiratory events, delayed discharge, and resource utilization in SDB patients undergoing ambulatory shoulder surgery compared to patients who do not receive ISB; and 4) To assess important analgesia related outcomes such as: time to onset of pain, intraoperative and postoperative opioid consumption, hourly and daily VAS pain scores, opioid related side effects, patient satisfaction with analgesia, and presence/absence of nerve block complications.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

TRIPLE

Enrollment

Conditions

Sleep Disordered Breathing Obstructive Sleep Apnea

Interventions

Interscalene BlockPROCEDURE

15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.

Superior Trunk Nerve BlockPROCEDURE

15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients ( \>18 to 80 years); * American Society of Anesthesiology (ASA) physical status I-IV; * Undergoing elective ambulatory shoulder surgery such as shoulder replacement, acromioplasty, rotator cuff repair, or Bankart procedure under general anesthesia. Exclusion Criteria: * Past history of head, neck or thoracic surgery (e.g., OSA corrective surgery); * Pregnancy or lactation; * Phrenic nerve stimulators; * Local anesthetic allergy; * Previous diaphragmatic paralysis; * Inability to communicate with health care providers or the research personnel, inability to perform breathing maneuvers such as spirometry, or inability to follow instructions.

Locations (2)

Women's College Hospital

Toronto, ON Ontario, Canada

Toronto Western Hospital

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Change in Oxygen desaturation index (ODI) from baseline to the night of surgery (post- operation) (N1).

All patients will undergo a portable overnight oximetry study at home to establish the baseline oxygen saturation measured hourly. Oxygen Desaturation Index (ODI), which is defined as a 4% drop in oxygenation from the baseline, and calculated as events occurring per hour during the recording time; the minimum and mean oxygen saturation ; and the cumulative total of recoded time below an oxygen saturation of 90%, CT90). Patients with preoperative ODI with more than a score of 10 will be considered at risk of SDB. A change from baseline will be examined and compared between the two groups.

Time frame: Time of measurements will be at baseline (pre operatively) and within 24 hours post-operatively (night of surgery)

Secondary Outcomes

Change in amplitude of diaphragmatic excursion with breathing maneuvers, between before and after surgery (measured by ultrasound)

Rate of diaphragmatic function (complete, partial, or none) will be assessed before and after surgery using M-Mode Ultrasound. Assessment will be performed during quiet breathing, sniffing, and deep breathing. After surgery diaphragmatic paresis will be indicated by a flat trace (absence of excursion) with quiet and deep breathing and/or with paradoxical motion. Measurement of amplitude of excursion will be made when partial paresis is observed. Using the sniff maneuver, complete hemi-diaphragmatic paresis (reduction of \>75% from baseline) and partial paresis (reduction of 25-75%from baseline) will be recorded. Rate will be assessed in the basal state (i.e. before regional anesthesia) to establish a baseline, and again in the post-operative period.

Time frame: Time of measurements will be within 1 hour before surgery, and within 1 hour after surgery. It will take around 10-15 minutes.

Change in pulmonary function before and after surgery, as measured by bedside spirometry

Change in pulmonary function tests \[Forced vital capacity (FVC), forced expiratory volume in 1s (FEV1), Expiratory reserve volume (ERV) and peak expiratory flow (PEF) \], between before and after surgery will be measured by bedside spirometry

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.